CRL Q4 2025 Earnings Call Summary

Summary of Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

Q4 2025 Revenue: $994.2 million, a 2.6% organic decline year-over-year.
Full Year 2025 Revenue: $4.02 billion, a 1.6% organic decrease.
Earnings Per Share (EPS): Q4 EPS was $2.39 (down 10.2% from $2.66 in Q4 2024); full-year EPS was nearly flat at $10.28 compared to $10.32 in 2024.
Operating Margin: Q4 margin decreased to 18.1% (down 180 basis points); full-year margin was 19.8% (down 10 basis points).
DSA Revenue: Q4 DSA revenue was $591.6 million (down 3.3%); full-year DSA revenue decreased 2.6%.
Net Book-to-Bill Ratio: Improved to 1.12x in Q4 from 0.82x in Q3.

2. Strategic Updates and Business Highlights

Acquisitions: CRL announced the acquisition of KF Cambodia (closed) and PathoQuest (expected to close soon), aimed at strengthening its NHP supply chain and enhancing biologics testing capabilities.
NAMS Development: Progress in New Approach Methodologies (NAMS) was highlighted, including the integration of AI and other technologies to support drug development.
Divestiture Plans: Ongoing processes to divest businesses representing approximately 7% of 2025 revenue, expected to be completed by 2026.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Expected to range from a 1% decline to flat organic growth, with operating margin improvement of 20 to 50 basis points.
EPS Guidance for 2026: Projected to be between $10.70 and $11.20, reflecting a 4% to 9% increase.
Segment Expectations:
- RMS: Anticipated low- to mid-single-digit decline due to lower NHP revenue.
- DSA: Expected to be slightly positive to low single-digit decrease, contingent on continued favorable demand trends.
- Manufacturing: Forecasted to rebound to low single-digit growth.

4. Challenges and Points of Concern

Revenue Declines: All business segments reported revenue declines, with notable softness in DSA and Manufacturing.
Operating Margin Pressures: Increased costs related to staffing and NHP sourcing impacted margins, particularly in Q1 2026.
Market Volatility: The biotech funding environment remains uncertain, with potential impacts on client demand and spending.
NHP Sourcing Costs: Higher-than-expected costs due to increased demand for studies and reliance on open market sourcing.

5. Notable Q&A Insights

NHP Dynamics: Management clarified the contrasting impacts of NHP demand on RMS and DSA, attributing challenges to timing and sourcing costs.
Demand Environment: Positive trends in client demand were noted, particularly from global biopharma, with a cautious optimism for continued improvement in 2026.
AI and NAMS: Management expressed confidence that AI would complement rather than disrupt their business, viewing it as an enabling technology for drug discovery.
Divestiture Process: Ongoing negotiations with potential buyers for divestitures were confirmed, with expectations for completion in the first half of 2026.

Overall, while CRL faced challenges in 2025, particularly in revenue and margins, strategic acquisitions and a cautiously optimistic outlook for 2026 suggest potential for recovery and growth in the coming year.

CRL — Charles River Laboratories International, Inc.